Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| 3PoBV | 3PoBV66 | U.S. | 1994 | HIV1 | B | Plasma | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | NRTI+IDV | 66 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46I, I54V, V82A | L24I | L10I, I62V, L63Q, A71V, I93L |
| >3PoBV66| 37 | codons 1-99 | clone 37 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QVQIEICGHKAIGTVLVGPTPANIIGRNLLTQLGCTLNF >3PoBV66| 39 | codons 1-99 | clone 39 PQITLWQRPIVTIKIGGQLKEALIDTGADDTVLEEMNLPGRWKPKIIGGIGGFVKVRQYD QVQIEICGHKAIGTVLVGPTPANIIGRNLLTQLGCTLNF >3PoBV66| 40 | codons 1-99 | clone 40 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEKMNLPGGWKPKLIGGIGGFVKVRQYD QVQIEICGHKAIGTVLVGPTPANIIGRNLLTQLGCTLNF >3PoBV66| 41 | codons 1-99 | clone 41 PQITLWQRPIVTIKIGGRLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QVQIEICGHKAIGTVLVGPTPANIIGRNLLTQLGCTLNF >3PoBV66| 42 | codons 1-99 | clone 42 PQITLWQRPIVTIKIGGQLKEALIDTGADDTVLEEMNLPGRWKPKIIGGIGGFVKVRQYD QVQIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF >3PoBV66| 43 | codons 1-99 | clone 43 PQITLWQRPIVTIKIGGQLKEALIDTGADDTVLEEMNLPGRWKPKIIGGIGGFVKVRQYD QVQIEICGHKAIGTVLVGPTPANIIGRNLLTQLGCTLNF >3PoBV66| 45 | codons 1-99 | clone 45 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QVQIEICGHKAIGTVLVGPTPANIIGRNLLTQLGCTLNF >3PoBV66| codons 1-99 PQITLWQRPIVTIKIGGQLKEALIDTGADDTVLEEMNLPGRWKPKIIGGIGGFVKVRQYD QVQIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF |
References
| Author | Title | Citation |
| Zhang, Y-M | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. | J Virol, 1997 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |